BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25062766)

  • 1. Experimental mutagenesis of huntingtin to map cleavage sites: different outcomes in cell and mouse models.
    Tebbenkamp AT; Xu G; Siemienski ZB; Janus C; Fromholt SE; Brown HH; Swing D; Tessarollo L; Borchelt DR
    J Huntingtons Dis; 2014; 3(1):73-86. PubMed ID: 25062766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.
    Schilling G; Savonenko AV; Klevytska A; Morton JL; Tucker SM; Poirier M; Gale A; Chan N; Gonzales V; Slunt HH; Coonfield ML; Jenkins NA; Copeland NG; Ross CA; Borchelt DR
    Hum Mol Genet; 2004 Aug; 13(15):1599-610. PubMed ID: 15190011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of proteolytic processes and enzymatic activities in the generation of huntingtin n-terminal fragments in an HEK293 cell model.
    Tebbenkamp AT; Crosby KW; Siemienski ZB; Brown HH; Golde TE; Borchelt DR
    PLoS One; 2012; 7(12):e50750. PubMed ID: 23236391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premature death and neurologic abnormalities in transgenic mice expressing a mutant huntingtin exon-2 fragment.
    Tebbenkamp AT; Swing D; Tessarollo L; Borchelt DR
    Hum Mol Genet; 2011 Apr; 20(8):1633-42. PubMed ID: 21307087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.
    Tebbenkamp AT; Green C; Xu G; Denovan-Wright EM; Rising AC; Fromholt SE; Brown HH; Swing D; Mandel RJ; Tessarollo L; Borchelt DR
    Hum Mol Genet; 2011 Jul; 20(14):2770-82. PubMed ID: 21515588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models.
    Schilling G; Klevytska A; Tebbenkamp AT; Juenemann K; Cooper J; Gonzales V; Slunt H; Poirer M; Ross CA; Borchelt DR
    J Neuropathol Exp Neurol; 2007 Apr; 66(4):313-20. PubMed ID: 17413322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.
    Kim YJ; Yi Y; Sapp E; Wang Y; Cuiffo B; Kegel KB; Qin ZH; Aronin N; DiFiglia M
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12784-9. PubMed ID: 11675509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
    Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
    Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
    Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
    J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.
    Lunkes A; Lindenberg KS; Ben-Haïem L; Weber C; Devys D; Landwehrmeyer GB; Mandel JL; Trottier Y
    Mol Cell; 2002 Aug; 10(2):259-69. PubMed ID: 12191472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of interleukin-1 type 1 receptor enhances the accumulation of mutant huntingtin in the striatum and exacerbates the neurological phenotypes of Huntington's disease mice.
    Wang CE; Li S; Li XJ
    Mol Brain; 2010 Nov; 3():33. PubMed ID: 21044321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin.
    Waldron-Roby E; Ratovitski T; Wang X; Jiang M; Watkin E; Arbez N; Graham RK; Hayden MR; Hou Z; Mori S; Swing D; Pletnikov M; Duan W; Tessarollo L; Ross CA
    J Neurosci; 2012 Jan; 32(1):183-93. PubMed ID: 22219281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
    J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.
    Schilling G; Becher MW; Sharp AH; Jinnah HA; Duan K; Kotzuk JA; Slunt HH; Ratovitski T; Cooper JK; Jenkins NA; Copeland NG; Price DL; Ross CA; Borchelt DR
    Hum Mol Genet; 1999 Mar; 8(3):397-407. PubMed ID: 9949199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysosomal proteases are involved in generation of N-terminal huntingtin fragments.
    Kim YJ; Sapp E; Cuiffo BG; Sobin L; Yoder J; Kegel KB; Qin ZH; Detloff P; Aronin N; DiFiglia M
    Neurobiol Dis; 2006 May; 22(2):346-56. PubMed ID: 16423528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
    Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
    Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.
    Graham RK; Deng Y; Slow EJ; Haigh B; Bissada N; Lu G; Pearson J; Shehadeh J; Bertram L; Murphy Z; Warby SC; Doty CN; Roy S; Wellington CL; Leavitt BR; Raymond LA; Nicholson DW; Hayden MR
    Cell; 2006 Jun; 125(6):1179-91. PubMed ID: 16777606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice.
    Bradford J; Shin JY; Roberts M; Wang CE; Sheng G; Li S; Li XJ
    J Biol Chem; 2010 Apr; 285(14):10653-61. PubMed ID: 20145253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.